This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): IPP-201101, CEP-33457, SyB 1001, rigerimod
Description: IPP-201101 modulates the signalling of CD4+ cells and may also interact with the T-reg pathway. The key element is that IPP-201101 has been designed to interact only with the CD4+ cells linked to Lupus and leaves intact the remaining immune system, allowing Lupus patients to be protected by a fully operational immune system unlike the currently used therapies such as high dose corticoids and immunosuppressants.
Cephalon and ImmuPharma
In November 2008, Cephalon and ImmuPharma announced that the companies have signed an Option Agreement providing Cephalon with an option to obtain an exclusive, worldwide license to Lupuzor for the treatment of Systemic Lupus Erythematosus. ImmuPharma is now conducting a large Phase IIb study of Lupuzor in patients in Europe and Latin America.
Under the terms of the option agreement, Cephalon will pay ImmuPharma a $15 million upfront option payment. If the Phase IIb studies are successful and if the option is exercised then the parties enter into an exclusive worldwide license agreement and ImmuPharma will receive a one-time license fee, milestone payments upon the achievement of regulatory milestones and royalties on commercial sales of Lupuzor. The various milestone payments which include sales milestones may total up to $500 million. Upon exercise of the option, Cephalon will assume all expenses for Phase III studies and subsequent...See full deal structure in Biomedtracker
Partners: SymBio Pharmaceuticals Ltd.
Additional information available to subscribers only: